Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in HR+/HER2- Advanced Breast Cancer
NCT06236269Phase 2Recruiting
- Sponsor
- SOLTI
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in breast cancer, sponsored by SOLTI. Primary endpoint: Change in CelTIL score. Started Mar 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06236269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236269.